Co-Chairs

Guy Donatiello

Senior Vice President
Intellectual Property at Endo Pharmaceuticals (Malvern, PA)

Co-Chairs’ Opening Remarks

April 24, 2017 8:00 am

Timothy X. Witkowski, M.S., J.D.

Head, US Chemistry Patents at Novartis Institutes for BioMedical Research (Cambridge, MA)

Co-Chairs’ Opening Remarks

April 24, 2017 8:00 am

Speakers

Paul A. Ainsworth

Director at Sterne, Kessler, Goldstein & Fox P.L.L.C. (Washington, DC)

The Ongoing Jurisdiction Debate: From Mylan to TC Heartland

April 24, 2017 1:45 pm

Andrew M. Alul

Partner at Taft Stettinius & Hollister LLP. (Chicago, IL)

Illusory Safe Harbors: Exploring Uncertainties in the Boundaries of 271 (e) (1) and the Scope of Divided and Induced Infringement

April 25, 2017 8:15 am

Brian Anderson

V.P. & Assist. General Counsel – IP Litigation at Allergan (Parsippany, NJ)

Examining the ITC as an Alternate Forum in an ANDA Challenge

April 25, 2017 11:00 am

Bradford J. (Jim) Badke

Partner at Sidley Austin LLP (New York, NY)

The Ongoing Jurisdiction Debate: From Mylan to TC Heartland

April 24, 2017 1:45 pm

Nicolas G. Barzoukas

Partner at Reed Smith LLP (Huston, TX)

The Ongoing Jurisdiction Debate: From Mylan to TC Heartland

April 24, 2017 1:45 pm

Richard J. Berman

Partner at Arent Fox LLP (Washington, DC)

Obviousness Update for PIV Litigation: Latest Developments in the Federal Courts and PTAB

April 24, 2017 4:00 pm

Honorable Tonianne Bongiovanni, U.S.M.J.

United States District Court at District of New Jersey (Trenton, NJ)

A Magistrate Judge’s Insights on ANDA Practice

April 25, 2017 11:30 am

Karen E. Brown, Ph.D.

Vice President & Chief Intellectual Property Counsel at Ironwood Pharmaceuticals (Cambridge, MA)

The Dollars, Cents and Due Diligence of Pharmaceutical Patent Life Cycle Management and Litigation Planning

April 24, 2017 10:00 am

Jared C. Bunker

Partner at Knobbe, Martens, Olson & Bear, LLP (Irvine, CA)

Illusory Safe Harbors: Exploring Uncertainties in the Boundaries of 271 (e) (1) and the Scope of Divided and Induced Infringement

April 25, 2017 8:15 am

Daniel Butrymowicz

Staff Attorney at Federal Trade Commission (Washington, DC)

FTC Keynote: Update on Reverse Payment Settlements and Other Antitrust Developments Concerning Brand Name and Generic Interests

April 25, 2017 1:30 pm

Honorable Christopher J. Burke, U.S.M.J.

United States District Court at District of Delaware (Wilmington, DE)

A Magistrate Judge’s Insights on ANDA Practice

April 25, 2017 11:30 am

Vincent L. Capuano, Ph.D.

Partner at Duane Morris LLP (Boston, MA)

Revisiting Use Codes and Carve-Out Cases in Light of the Final MMA Rule

April 24, 2017 12:00 pm

Kathleen B. Carr

Member at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (Boston, MA)

The Dollars, Cents and Due Diligence of Pharmaceutical Patent Life Cycle Management and Litigation Planning

April 24, 2017 10:00 am

Corey M. Casey

Shareholder at Polsinelli PC (Kansas City, MO)

Workshop B – Biosimilars 2.0 for the Paragraph IV Litigator

April 26, 2017 1:00 pm

Honorable Ruben Castillo, Chief Judge

United States District Court, Northern District of Illinois (Chicago, IL)

A View from the Bench: The Federal Judges Speak on Paragraph IV Litigation

April 24, 2017 4:45 pm

Alan B. Clement

Partner at Locke Lord LLP (New York, NY)

The REMS Conundrum: Exploring Challenges for Both Brands and Generics

April 25, 2017 3:15 pm

Dominic A. Conde

Partner at Fitzpatrick, Cella, Harper & Scinto (New York, NY)

Understanding the Continuing Impact of 101 on Orange Book Listed-Method Claims

April 24, 2017 3:15 pm

David G. Conlin

Member at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (Boston, MA)

Case Studies in New Ethical Developments Impacting Paragraph IV Practice

April 25, 2017 4:00 pm

Gregory F. Corbett

Shareholder at Wolf, Greenfield & Sacks, P.C. (Boston, MA)

Illusory Safe Harbors: Exploring Uncertainties in the Boundaries of 271 (e) (1) and the Scope of Divided and Induced Infringement

April 25, 2017 8:15 am

Steven M. Coyle

Partner and Pharmaceutical Litigation Group Leader at Cantor Colburn LLP (Hartford, CT)

The Ongoing Jurisdiction Debate: From Mylan to TC Heartland

April 24, 2017 1:45 pm

Joshua P. Davis

Partner at Reed Smith LLP (Huston, TX)

Alternate Forums for Pharmaceutical Patent Challenges

PTAB Pharmaceutical Patent Invalidity Round-Up: Update on Wins, Losses and Appeals

April 25, 2017 10:15 am

Mark T. Deming

Patent Attorney at Polsinelli PC (Chicago, IIL)

Obviousness Update for PIV Litigation: Latest Developments in the Federal Courts and PTAB

April 24, 2017 4:00 pm

Michael R. Dzwonczyk

Partner at Sughrue Mion PLLC (Washington, DC)

Obviousness Update for PIV Litigation: Latest Developments in the Federal Courts and PTAB

April 24, 2017 4:00 pm

Joseph Evall

Partner at Gibson, Dunn & Crutcher LLP

Illusory Safe Harbors: Exploring Uncertainties in the Boundaries of 271 (e) (1) and the Scope of Divided and Induced Infringement

April 25, 2017 8:15 am

Uma N. Everett

Director at Sterne, Kessler, Goldstein & Fox P.L.L.C. (Washington, DC)

Illusory Safe Harbors: Exploring Uncertainties in the Boundaries of 271 (e) (1) and the Scope of Divided and Induced Infringement

April 25, 2017 8:15 am

Lisa M. Ferri

Partner at Mayer Brown LLP (New York, NY)

The Politics and Policy of Pharmaceutical Patents in the New Administration: Town Hall

April 24, 2017 8:15 am

Karin Ferriter

Deputy Chief Policy Officer, Office of Policy and International Affairs at USPTO (Alexandria, VA)

USPTO Keynote: Patent Rights and Generic Entry – An International Perspective

April 24, 2017 9:00 am

Aron Fischer

Partner at Patterson Belknap Webb & Tyler LLP (New York, NY)

Case Studies in New Ethical Developments Impacting Paragraph IV Practice

April 25, 2017 4:00 pm

Wanda French-Brown

Counsel at Baker & Hostetler LLP (New York, NY)

Examining the ITC as an Alternate Forum in an ANDA Challenge

April 25, 2017 11:00 am

Ralph J. Gabric

Shareholder at Brinks Gilson & Lione (Chicago, IL)

The PTAB Live: Thoughts on Practice, Procedure, IPRs and More in the World of Pharmaceutical Patent Validity Challenges

April 25, 2017 9:00 am

Barry P. Golob

Vice Chair, Intellectual Property Department at Cozen O’Connor (Washington, DC)

A View from the Bench: The Federal Judges Speak on Paragraph IV Litigation

April 24, 2017 4:45 pm

George G. Gordon

Partner at Dechert LLP (Philadelphia, PA)

The Politics and Policy of Pharmaceutical Patents in the New Administration: Town Hall

April 24, 2017 8:15 am

Vishal C. Gupta

Partner at Steptoe & Johnson LLP (New York, NY)

Workshop A – IPR Strategies and Parallel Proceedings Master Class: Devising Strategies for IPR Best Practices and Navigating Dual Forums in Hatch-Waxman Litigation

April 26, 2017 8:30 am

Averie K. Hason

Assistant General Patent Counsel, IP Litigation NY/NJ at Eli Lilly and Company (Bridgewater, NJ)

Illusory Safe Harbors: Exploring Uncertainties in the Boundaries of 271 (e) (1) and the Scope of Divided and Induced Infringement

April 25, 2017 8:15 am

Benjamin C. Hsing

Partner at Baker & Hostetler LLP (New York, NY)

Case Studies in New Ethical Developments Impacting Paragraph IV Practice

April 25, 2017 4:00 pm

Lisa A. Jakob

Legal Director, IP Litigation at Merck & Company (Rahway, NJ)

The Ongoing Jurisdiction Debate: From Mylan to TC Heartland

April 24, 2017 1:45 pm

Kurt R. Karst

Director at Hyman, Phelps & McNamara, P.C. (Washington, DC)

Focus on the Final MMA Rule
Q&A with the FDA on the Final MMA Rule: Understanding the Impact for Hatch-Waxman Practice

April 24, 2017 11:00 am

James Kellerman

Vice President, Intellectual Property at Astellas (Northbrook, IL)

Case Studies in New Ethical Developments Impacting Paragraph IV Practice

April 25, 2017 4:00 pm

James M. (Jim) Lennon

Partner at Young Conaway Stargatt & Taylor, LLP (Wilmington, DE)

A Magistrate Judge’s Insights on ANDA Practice

April 25, 2017 11:30 am

Honorable Jose L. Linares, U.S.D.J.

United States District Court at District of New Jersey (Newark, NJ)

A View from the Bench: The Federal Judges Speak on Paragraph IV Litigation

April 24, 2017 4:45 pm

Josephine Liu, Ph.D., J.D.

Head, US IP Litigation at Sandoz Inc. (Princeton, NJ)

Obviousness Update for PIV Litigation: Latest Developments in the Federal Courts and PTAB

April 24, 2017 4:00 pm

Laura A. Lydigsen

Shareholder at Brinks Gilson & Lione (Chicago, IL)

Alternate Forums for Pharmaceutical Patent Challenges

PTAB Pharmaceutical Patent Invalidity Round-Up: Update on Wins, Losses and Appeals

April 25, 2017 10:15 am

Honorable Kimberly McGraw

Administrative Patent Judge
Patent Trial and Appeal Board at United States Patent and Trademark Office (Alexandria, VA)

The PTAB Live: Thoughts on Practice, Procedure, IPRs and More in the World of Pharmaceutical Patent Validity Challenges

April 25, 2017 9:00 am

Markus H. Meier

Assistant Director, Health Care Division, Bureau of Competition at Federal Trade Commission

William L. Mentlik

Partner at Lerner, David, Littenberg, Krumholz & Mentlik, LLP (Westfield, NJ)

Revisiting Use Codes and Carve-Out Cases in Light of the Final MMA Rule

April 24, 2017 12:00 pm

Don J. Mizerk

Partner at Husch Blackwell LLP (Chicago, IL)

Reverse Payment Settlements: The Industry Response

April 25, 2017 2:15 pm

John J. Molenda, Ph.D.

Partner at Steptoe & Johnson LLP (New York, NY)

The Ongoing Jurisdiction Debate: From Mylan to TC Heartland

April 24, 2017 1:45 pm

Gregory A. Morris, Ph.D.

Partner, Leader, Life Sciences Litigation Practice Group at Honigman Miller Schwartz and Cohn LLP (Chicago, IL)

Alternate Forums for Pharmaceutical Patent Challenges

PTAB Pharmaceutical Patent Invalidity Round-Up: Update on Wins, Losses and Appeals

April 25, 2017 10:15 am

Honorable Brian P. Murphy

Lead Administrative Patent Judge at Patent Trial and Appeal Board, USPTO (Alexandria, VA)

The PTAB Live: Thoughts on Practice, Procedure, IPRs and More in the World of Pharmaceutical Patent Validity Challenges

April 25, 2017 9:00 am

Jeffrey N. Myers, Ph.D.

Vice President & Assistant General Counsel at Pfizer Inc (New York, NY)

The Dollars, Cents and Due Diligence of Pharmaceutical Patent Life Cycle Management and Litigation Planning

April 24, 2017 10:00 am

Steven A. Nash

Senior Patent Counsel at Xellia Pharmaceuticals, Inc. (Raleigh, NC)

On Sale Bar – Round II: Understanding The Impact of Helsinn on Pharmaceutical Patents in a Post-AIA Setting

April 24, 2017 2:30 pm

Joseph M. O’Malley, Jr.

Partner at Paul Hastings LLP (New York, NY)

On Sale Bar – Round II: Understanding The Impact of Helsinn on Pharmaceutical Patents in a Post-AIA Setting

April 24, 2017 2:30 pm

Anil Patel, Ph.D.

Counsel at Kilpatrick Townsend & Stockton LLP (Atlanta, GA)

Revisiting Use Codes and Carve-Out Cases in Light of the Final MMA Rule

April 24, 2017 12:00 pm

Martin B. Pavane

Vice Chair, Intellectual Property Department
Co-Chair, Hatch-Waxman & Biologics Litigation at Cozen O’Connor (New York, NY)

Understanding the Continuing Impact of 101 on Orange Book Listed-Method Claims

April 24, 2017 3:15 pm

Honorable Roy Payne, U.S.M.J.

United States District Court at Eastern District of Texas (Marshall, TX)

A Magistrate Judge’s Insights on ANDA Practice

April 25, 2017 11:30 am

Lisa B. Pensabene

Partner at O’Melveny & Myers LLP (New York, NY)

Obviousness Update for PIV Litigation: Latest Developments in the Federal Courts and PTAB

April 24, 2017 4:00 pm

Kevin J. Post

Partner at Ropes & Gray LLP (New York)

The Dollars, Cents and Due Diligence of Pharmaceutical Patent Life Cycle Management and Litigation Planning

April 24, 2017 10:00 am

Filko Prugo

Partner at O’Melveny & Myers LLP (New York, NY)

The PTAB Live: Thoughts on Practice, Procedure, IPRs and More in the World of Pharmaceutical Patent Validity Challenges

April 25, 2017 9:00 am

Mark Rachlin

Senior Patent Counsel-Litigation at GlaxoSmithKline (King of Prussia, PA)

Case Studies in New Ethical Developments Impacting Paragraph IV Practice

April 25, 2017 4:00 pm

Honorable Teresa Rea

Partner at Crowell & Moring LLP (Washington, DC) (Former Acting Under Secretary of Commerce for Intellectual Property and Former Acting Director of the United States Patent and Trademark Office)

The Politics and Policy of Pharmaceutical Patents in the New Administration: Town Hall

April 24, 2017 8:15 am

Robert D. Rhoad

Partner at Dechert LLP (Princeton, NJ)

A Magistrate Judge’s Insights on ANDA Practice

April 25, 2017 11:30 am

Katharine R. Rice

Corporate Counsel at Gilead Sciences (Foster City, CA)

The REMS Conundrum: Exploring Challenges for Both Brands and Generics

April 25, 2017 3:15 pm

Irena Royzman, Ph.D.

Co-Chair, Biotechnology Practice at Patterson Belknap Webb & Tyler LLP (New York, NY)

A View from the Bench: The Federal Judges Speak on Paragraph IV Litigation

April 24, 2017 4:45 pm

Richard T. Ruzich

Partner at Taft Stettinius & Hollister LLP (Chicago, IL)

On Sale Bar – Round II: Understanding The Impact of Helsinn on Pharmaceutical Patents in a Post-AIA Setting

April 24, 2017 2:30 pm

Mark W. Ryan

Partner at Mayer Brown LLP (Washington, DC)

Reverse Payment Settlements: The Industry Response

April 25, 2017 2:15 pm

Margaret J. Sampson

Partner at Baker Botts L.L.P. (Austin, TX)

Focus on the Final MMA Rule
Q&A with the FDA on the Final MMA Rule: Understanding the Impact for Hatch-Waxman Practice

April 24, 2017 11:00 am

Honorable Robert W. Schroeder III, U.S.D. J. (invited)

United States District Court, Eastern District of Texas (Texarkana, TX)

Pearl T. L. Siew

Senior Vice President and Head, Intellectual Property at Eagle Pharmaceuticals, Inc. (Woodcliff Lake, NJ)

Alternate Forums for Pharmaceutical Patent Challenges

PTAB Pharmaceutical Patent Invalidity Round-Up: Update on Wins, Losses and Appeals

April 25, 2017 10:15 am

Paul Simboli

Vice President, Intellectual Property & Asst. General Counsel at Depomed, Inc (Newark, CA)

Revisiting Use Codes and Carve-Out Cases in Light of the Final MMA Rule

April 24, 2017 12:00 pm

Michael Sitzman

Partner at Gibson, Dunn & Crutcher LLP (San Francisco, CA)

Revisiting Use Codes and Carve-Out Cases in Light of the Final MMA Rule

April 24, 2017 12:00 pm

Stephen C. Stout, Ph.D.

Partner at Vinson & Elkins LLP (Austin, TX )

Alternate Forums for Pharmaceutical Patent Challenges

PTAB Pharmaceutical Patent Invalidity Round-Up: Update on Wins, Losses and Appeals

April 25, 2017 10:15 am

Paul B. Sudentas

Attorney at Locke Lord LLP (New York, NY)

Understanding the Continuing Impact of 101 on Orange Book Listed-Method Claims

April 24, 2017 3:15 pm

Sheila N. Swaroop

Partner at Knobbe, Martens, Olson & Bear, LLP (Irvine, CA)

Examining the ITC as an Alternate Forum in an ANDA Challenge

April 25, 2017 11:00 am

Jennifer C. Tempesta

Partner at Baker Botts LLP (New York, NY)

Reverse Payment Settlements: The Industry Response

April 25, 2017 2:15 pm

Vince Thomas

Senior Managing Director at FTI Consulting (Chicago, IL)

The Dollars, Cents and Due Diligence of Pharmaceutical Patent Life Cycle Management and Litigation Planning

April 24, 2017 10:00 am

Erin Ator Thomson

Counsel at Vinson & Elkins LLP (Austin, TX )

Workshop B – Biosimilars 2.0 for the Paragraph IV Litigator

April 26, 2017 1:00 pm

Maryll W. Toufanian, J.D.

Deputy Director, Office of Generic Drug Policy
Office of Generic Drugs, CDER at U.S. Food and Drug Administration (Silver Spring, MD)

Focus on the Final MMA Rule
Q&A with the FDA on the Final MMA Rule: Understanding the Impact for Hatch-Waxman Practice

April 24, 2017 11:00 am

Shashank Upadhye

Partner at Amin Talati & Upadhye (Chicago, IL)

The Politics and Policy of Pharmaceutical Patents in the New Administration: Town Hall

April 24, 2017 8:15 am

Tedd W. Van Buskirk

Partner at Lerner David Littenberg Krumholz & Mentlik, LLP (Westfield, NJ)

The REMS Conundrum: Exploring Challenges for Both Brands and Generics

April 25, 2017 3:15 pm

Laura A. Vogel

Partner at Barclay Damon LLP (Boston, MA)

Workshop A – IPR Strategies and Parallel Proceedings Master Class: Devising Strategies for IPR Best Practices and Navigating Dual Forums in Hatch-Waxman Litigation

April 26, 2017 8:30 am

Mark E. Waddell

Partner at Loeb & Loeb (New York, NY)

The Politics and Policy of Pharmaceutical Patents in the New Administration: Town Hall

April 24, 2017 8:15 am

Peter Waibel

Head, US Patent Litigation at Novartis Pharmaceuticals Corporation (East Hanover, NJ)

Understanding the Continuing Impact of 101 on Orange Book Listed-Method Claims

April 24, 2017 3:15 pm

Bruce M. Wexler

Partner at Paul Hastings LLP (New York, NY)

Understanding the Continuing Impact of 101 on Orange Book Listed-Method Claims

April 24, 2017 3:15 pm

Brandon M. White

Partner at Perkins Coie LLP (Washington, DC)

Obviousness Update for PIV Litigation: Latest Developments in the Federal Courts and PTAB

April 24, 2017 4:00 pm

Jason A. Wietjes

Shareholder at Polsinelli PC (Dallas, TX)

Understanding the Continuing Impact of 101 on Orange Book Listed-Method Claims

April 24, 2017 3:15 pm

Ha Kung Wong

Partner at Fitzpatrick, Cella, Harper & Scinto (New York, NY)

Workshop A – IPR Strategies and Parallel Proceedings Master Class: Devising Strategies for IPR Best Practices and Navigating Dual Forums in Hatch-Waxman Litigation

April 26, 2017 8:30 am

Alyson L. Wooten PharmD

Attorney at Kilpatrick Townsend & Stockton LLP (Atlanta, GA)

Workshop A – IPR Strategies and Parallel Proceedings Master Class: Devising Strategies for IPR Best Practices and Navigating Dual Forums in Hatch-Waxman Litigation

April 26, 2017 8:30 am